NAFLD / MASLD Stress and HPA Axis Impact: What the Evidence Shows

What Is the HPA Axis and Why Does It Matter for Liver Disease?

The hypothalamic-pituitary-adrenal axis is the body's primary stress-response system. When the brain perceives a threat, the hypothalamus releases corticotropin-releasing hormone (CRH), which triggers pituitary secretion of adrenocorticotropic hormone (ACTH), which then drives adrenal cortisol release. In short bursts, this response is protective. Sustained activation, however, keeps circulating cortisol elevated for weeks or months, and that prolonged exposure causes measurable damage to metabolic organs, including the liver [1].

How Cortisol Reaches the Liver

Hepatocytes express glucocorticoid receptors at high density. When cortisol binds these receptors, it activates transcription factors that upregulate lipogenic enzymes, particularly SREBP-1c and ChREBP, while simultaneously suppressing beta-oxidation pathways [2]. The net result is accelerated triglyceride synthesis and reduced fat clearance, the metabolic signature of steatosis.

Insulin Resistance as the Central Link

Cortisol also blunts insulin signaling in skeletal muscle and adipose tissue. Peripheral insulin resistance forces the pancreas to raise insulin output, and chronically elevated insulin further stimulates hepatic de novo lipogenesis [3]. A 2021 meta-analysis of 14 prospective cohort studies (N = 58,404) found that people with the highest perceived stress scores had a 37% higher risk of metabolic syndrome compared with those in the lowest quartile (OR 1.37, 95% CI 1.18 to 1.59, P<0.001) [4]. Metabolic syndrome and MASLD share this insulin-resistance root.

Visceral Fat as an Amplifier

Cortisol preferentially promotes visceral adiposity. Visceral adipose tissue releases free fatty acids (FFAs) directly into portal circulation, delivering a concentrated lipid load to the liver [5]. In people with MASLD, this portal FFA flux is already elevated, and chronic HPA activation compounds it. A cross-sectional study published in Hepatology (N = 612) found that waist-to-hip ratio, a visceral fat proxy, correlated more strongly with hepatic steatosis grade than body mass index alone [6].

Evidence Linking Psychological Stress to NAFLD / MASLD Progression

Observational data connecting stress to liver disease has grown substantially since 2015. The mechanistic case above is supported by clinical and epidemiological findings that span multiple study designs.

Cohort and Cross-Sectional Studies

A Korean cross-sectional study (N = 4,471) published in PLOS ONE found that high occupational stress scores were independently associated with ultrasonographically confirmed fatty liver (adjusted OR 1.43, 95% CI 1.12 to 1.82) after adjusting for alcohol, BMI, and exercise [7]. The association held across both sexes.

A separate prospective analysis from the Rotterdam Study (N = 3,021) found that depressive symptoms, a known marker of HPA dysregulation, predicted incident NAFLD over a 6-year follow-up (HR 1.29, 95% CI 1.04 to 1.60) [8]. Depression and HPA overactivation co-occur at high rates, and the Rotterdam data suggest that the physiological overlap has real hepatic consequences.

Biomarker Evidence

Salivary cortisol profiling in 89 patients with biopsy-confirmed MASLD showed a flattened diurnal cortisol slope compared with matched controls, a pattern consistent with HPA dysregulation rather than simple acute stress [9]. Flattened slope correlates with higher NAS (NAFLD Activity Score) in that cohort.

The table below organizes the evidence hierarchy from mechanism to trial:

| Level | Finding | Source | |---|---|---| | Molecular | Glucocorticoid receptor activation upregulates SREBP-1c in hepatocytes | [2] | | Metabolic | Cortisol excess causes peripheral insulin resistance | [3] | | Epidemiological | High stress score, OR 1.43 for fatty liver | [7] | | Prospective cohort | Depression predicts incident NAFLD, HR 1.29 | [8] | | Biomarker | Flattened cortisol slope in biopsy-confirmed MASLD | [9] |

Sleep Disruption, Circadian HPA Rhythm, and Liver Fat

Sleep is the primary regulator of the diurnal cortisol curve. Disrupted sleep raises late-evening cortisol, blunts the normal morning peak, and creates the same flattened slope described in MASLD patients above [10].

Short Sleep and MASLD Prevalence

A 2020 cross-sectional analysis of NHANES data (N = 6,905) found that adults sleeping fewer than 6 hours per night had a 50% higher prevalence of elevated ALT compared with those sleeping 7 to 8 hours (OR 1.50, 95% CI 1.14 to 1.97) [11]. Elevated ALT is a common clinical surrogate for hepatic steatosis in primary care settings.

Obstructive Sleep Apnea and Fibrosis Risk

Obstructive sleep apnea (OSA) combines intermittent hypoxia with recurrent cortisol surges. A meta-analysis of 18 studies (N = 2,183) found that OSA was independently associated with more advanced hepatic fibrosis in MASLD patients (OR 2.01, 95% CI 1.36 to 2.97) [12]. CPAP therapy reduced ALT by an average of 9.6 IU/L across five included RCTs.

Clinicians managing MASLD should screen for OSA routinely, particularly in patients with BMI >30 or neck circumference >40 cm, because treating apnea may directly reduce cortisol-driven liver injury.

Physical Activity: Dose, Modality, and Hepatic Fat Reduction

Exercise is the best-studied non-pharmacological intervention for MASLD. It reduces hepatic fat through multiple pathways, including lowered cortisol, improved insulin sensitivity, and direct upregulation of hepatic fatty acid oxidation [13].

Aerobic Exercise

A 2021 systematic review and meta-analysis of 22 RCTs (N = 1,530) found that aerobic exercise reduced liver fat content by a mean of 3.37% (absolute, measured by MRI or spectroscopy) compared with sedentary controls (P<0.001) [13]. Doses of 150 to 300 minutes per week at moderate intensity (60 to 70% VO2 max) produced the most consistent results.

The AASLD 2023 Practice Guidance states: "Structured aerobic exercise and resistance training are recommended as first-line interventions to reduce hepatic steatosis in patients with MASLD, independent of weight change" [14].

Resistance Training

Resistance training provides a complementary benefit. A 12-week RCT (N = 53) comparing resistance training to aerobic exercise in MASLD patients found equivalent reductions in hepatic fat by MR spectroscopy (resistance: 3.2% reduction; aerobic: 3.5% reduction; P = 0.74 between groups) [15]. Resistance training also reduced fasting insulin by 18% vs. 12% in the aerobic group, suggesting greater insulin-sensitizing effect per session.

HPA Axis Normalization With Exercise

Moderate-intensity exercise normalizes the HPA axis over 8 to 12 weeks. A controlled trial (N = 42) measuring diurnal salivary cortisol before and after a 10-week supervised walking program found a 22% reduction in evening cortisol and restoration of the morning-peak-to-evening trough ratio [16]. That normalization is clinically relevant for MASLD because, as described earlier, flattened diurnal cortisol directly correlates with disease severity.

Dietary Patterns That Counter HPA-Driven Hepatic Fat

Diet modifies MASLD through caloric restriction, macronutrient composition, and direct effects on cortisol metabolism. Fructose, in particular, amplifies hepatic lipogenesis via the same SREBP-1c pathway activated by glucocorticoids [17].

Mediterranean Diet

The PREDIMED-Plus sub-study examined liver outcomes in 294 participants randomized to an energy-restricted Mediterranean diet vs. A standard low-fat diet over 12 months. Hepatic steatosis index fell by 39% in the Mediterranean diet group vs. 7% in controls (P<0.001) [18]. The Mediterranean diet's polyphenol content may also attenuate cortisol-induced oxidative stress in hepatocytes.

Fructose and Added Sugar Restriction

Added sugar contributes 14.6% of total calories in the average US adult diet, according to NHANES 2011 to 2014 data [19]. A 9-day controlled isocaloric study (N = 41) replacing dietary fructose with starch reduced hepatic de novo lipogenesis from 26.9% to 16.9% of VLDL-TG (P<0.001) [17]. Even without caloric deficit, reducing fructose directly reduces the substrate for hepatic fat accumulation.

Caloric Restriction and Weight Loss Thresholds

Guidelines from the European Association for the Study of the Liver (EASL) specify that a 7 to 10% reduction in body weight produces histological improvement in steatohepatitis, and a 10% loss is associated with fibrosis regression in approximately 45% of patients [20]. Caloric restriction of 500 to 1,000 kcal/day below maintenance is the recommended starting point.

Pharmacological Options: Where They Fit Alongside Stress Management

Lifestyle interventions address the HPA-driven pathway directly. Pharmacological therapies target downstream metabolic consequences and may be added when lifestyle changes alone produce insufficient response.

Resmetirom (Rezdiffra)

The FDA approved resmetirom in March 2024 for adults with noncirrhotic MASH and fibrosis stages F2, F3. In the MAESTRO-NASH trial (N = 966), resmetirom 100 mg daily achieved MASH resolution without fibrosis worsening in 25.9% of patients vs. 14.2% placebo (P<0.001), and fibrosis improvement of at least one stage in 24.2% vs. 14.6% (P<0.001) [21].

GLP-1 Receptor Agonists

Semaglutide 2.4 mg weekly showed MASH resolution in 59% of patients vs. 17% placebo in a 72-week phase 3 trial (N = 800, NEJM 2023) [22]. GLP-1 receptor agonists reduce cortisol-amplified visceral adiposity and improve hepatic insulin sensitivity, making them mechanistically complementary to stress management.

The 2023 American Association for the Study of Liver Diseases guidance notes: "GLP-1 receptor agonist therapy should be considered in patients with MASLD and concurrent type 2 diabetes or obesity when lifestyle modification alone is insufficient" [14].

Tirzepatide

A phase 2 RCT (N = 157) published in NEJM Evidence (2024) found that tirzepatide 10 mg or 15 mg weekly resolved MASH in 62% and 74% of patients respectively vs. 13% placebo (P<0.001 for both doses) [23]. The dual GIP/GLP-1 mechanism produces greater visceral fat reduction than semaglutide alone in head-to-head metabolic comparisons.

Stress Reduction Interventions With Hepatic Endpoints

Few RCTs have used liver histology or MRI fat as primary endpoints for stress-reduction interventions. The available evidence uses biomarker and metabolic surrogates, which is an acknowledged limitation of the field.

Mindfulness-Based Stress Reduction (MBSR)

A 2022 RCT (N = 84) randomized adults with MASLD confirmed by FibroScan to 8-week MBSR vs. Health education control. The MBSR group showed a 12% reduction in controlled attenuation parameter (CAP) score at 8 weeks vs. 3% in controls (P = 0.04), alongside a 17% reduction in fasting cortisol [24]. CAP score is a validated ultrasound-based measure of hepatic steatosis.

Cognitive Behavioral Therapy (CBT)

A pilot RCT (N = 36) combining CBT for stress with dietary counseling produced greater reductions in ALT (mean change: 21 IU/L vs. 11 IU/L, P = 0.03) and waist circumference at 16 weeks compared with dietary counseling alone [25]. The sample size limits generalizability, but the direction of effect is consistent with the mechanistic model.

Yoga and Structured Relaxation

A 12-week yoga RCT (N = 66) in NAFLD patients found reductions in BMI, fasting glucose, and ALT alongside a 14% fall in serum cortisol compared with a wait-list control group [26]. These results should be interpreted cautiously given the small sample and lack of histological confirmation.

Practical Clinical Framework for HPA-Aware MASLD Management

Managing MASLD requires addressing both the downstream hepatic injury and the upstream HPA drivers where they are present. The following framework organizes interventions by mechanism.

Step 1: Assess Stress and Sleep

Obtain a brief psychosocial history at the first visit. Use the Perceived Stress Scale (PSS-10) and screen for OSA with the STOP-BANG questionnaire. Patients with PSS-10 >20 or STOP-BANG >3 should have those conditions addressed concurrently with metabolic therapy, not sequentially.

Step 2: Prioritize Exercise Early

Prescribe 150 minutes per week of moderate aerobic activity as a specific, measurable instruction. Add two resistance training sessions per week. Structured exercise normalizes HPA tone within 8 to 12 weeks while reducing hepatic fat independently of weight loss [13].

Step 3: Implement Dietary Change

Target a 500 to 1,000 kcal/day deficit using a Mediterranean-pattern diet. Restrict added fructose (goal <25 g/day from added sources). Track progress with hepatic steatosis biomarkers (FIB-4 index, CAP score) at 3 to 6 months.

Step 4: Consider Pharmacotherapy at 6 Months

If FIB-4 remains elevated or FibroScan shows persistent significant steatosis after 6 months of structured lifestyle change, evaluate for GLP-1 receptor agonist therapy or referral for hepatology assessment including resmetirom eligibility.

Step 5: Retest HPA Biomarkers

Salivary cortisol slope testing at baseline and 12 weeks can document HPA normalization. This is not yet standard of care but provides objective feedback on whether stress interventions are producing physiological change.